Infliximab for juvenile idiopathic arthritis-associated uveitis

Clinical and Experimental Ophthalmology

Volumn 33, Issue 5, 2005, Pages 461-468

  Richards, Josephine C ^a   Tay Kearney, Mei Ling ^a,b   Murray, Kevin ^a   Manners, Prue ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LIONS EYE INSTITUTE   (Australia)

Author keywords

Adalimumab; Anti TNF therapy; Chronic anterior uveitis; Etanercept; Infliximab; Juvenile idiopathic arthritis

Indexed keywords

ANTIGLAUCOMA AGENT; ANTIHISTAMINIC AGENT; IMMUNOMODULATING AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ANTIBODY; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EYE INFLAMMATION; EYE SURGERY; FEMALE; HUMAN; IMMUNOMODULATION; INTRAOCULAR PRESSURE; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALE; PRURITUS; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RHINORRHEA; SCHOOL CHILD; SNEEZING; UVEITIS; CHILD; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 33644805174     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2005.01062.x     Document Type: Article

References (34)

1. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2:346-57.
2. Andreakos E, Taylor PC, Feldman M. Monoclonal antibodies in inflammatory diseases. Curr Opin Biothechnol 2002;13:615-20.
3. Shanahan JC, St. Clair EW. Tumour necrosis factor-alpha blockade: A novel therapy for rheumatic disease. Clin Immunol 2002;103:231-42.
4. Braun J. Reply. Arthritis Rheum 2002;46:2822-3.
5. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
6. Su C, Salzberg BA, Lewis JD et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-84.
7. Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003;325:75-92.
8. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002;16:361-78.
9. Reiff A, Tyakei S, Stout A et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44:1411-15.
10. Reiff A. Long-term outcome of etanercept treatment in children with treatment refractory uveitis. Arthritis Rheum 2001;48:2079-80.
11. Smith JR, Levinson RD, Holland GN et al. Differential efficacy of tumour necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001;45:252-7.
12. Reddy A. Does etanercept induce uveitis. Br J Ophthalmol 2003;87:925.
13. Hashkes P, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:645-6.
14. Tiliakos A, Tiliakos N. Ocular inflammatory disease in patients with RA taking etanercept: Is discontinuation necessary? J Rheumatol 2003;30:2727.
15. Sfikakis P, Theodossiadis P, Katsiari C et al. Effect of infliximab in sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6.
16. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J et al. Effect of infliximab on sight threatening panuveitis in Behcet's disease. Lancet 2001;358:1644.
17. Kruirhof E, Kestelyn P, Elewut C et al. Successful use of infliximab in a patient with treatment resistant spondylarthropathy related uveitis. Ann Rheum Dis 2002;61:470.
18. El-Shabrawi Y, Hermann J. Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive HLA-B27 associated anterior uveitis: Comment on the article by Brandt et al. Arthritis Rheum 2001;46:2821-2.
19. Fries W, Giofre MR, Catanoso M, Gullo RL. Treatment of acute uveitis associated with Crohns disease and sacroileitis with infliximab. Am J Gastroenterol 2002;97:499-500.
20. Murphy CC, Ayliffe WH, Booth A et al. Tumour necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6.
21. Mangge H, Heinzl B, Grubbauer H-M et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 2003;23:258-61.
22. Honkanen V, Lappi M, Koskinen L, Lindahl P. Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis [Abstract]. Arthritis Rheum 2001;44(S9):S292.
23. Kahn PJ, Weiss M, Imundo LF, Levy DM. Favourable response to higher dose infliximab in refractory uveitis: Eleven cases. Arthritis Rheum 2004;50(S9):S92:no.7.
24. Saurenmann RK, Rose J, Tyrell P et al. The effect of anti TNF-alpha treatment in children with uveitis. Arthritis Rheum 2004;50(S9):S92:no.79.
25. Nussenblatt RB, Whitcup SM, Palestine AG. Examination of the patient with uveitis. In: Nussenblatt RB, ed. Uveitis Fundamentals and Clinical Practice, 2nd edn. St Louis, MO: Mosby, 1995;58-68.
26. Bondeson J, Mani R. Tumour necrosis factor-alpha as therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: The clinical experience with infliximab. Int J Clin Pract 2001;55:211-16.
27. van Deventer SJH. New biological therapies in inflammatory bowel diseases. Best Pract Clin Res 2003;17:119-30.
28. Stein R, Hanauer S. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23:429-48.
29. Diamanti A, Castro M, Papadatou B, Ferretti F, Gambarara M. Severe anaphylactic reaction to infliximab in pediatric patients with Crohns disease. J Pediatr 2002;140:636-7.
30. Youdim A, Vasiliauskas EA, Targan SR et al. A pilot study of adalimumab in infliximab allergic patients. Inflamm Bowel Dis 2004;10:333-8.
31. Chiefetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2004;98:1315-24.
32. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005;4:162-70.
33. Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002;69:170-2.
34. Centers for Disease Control and Prevetion (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor alpha-California 2002-2003. Morb Mortal Wkly Rep 2004;53:683-6.